Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
11:51am, Thursday, 18'th Sep 2025
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
08:57am, Thursday, 18'th Sep 2025
Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.
3 Dividend Growth Stocks You Can Buy and Forget About
04:50am, Thursday, 18'th Sep 2025
If you want a good dividend growth stock to buy and not worry about, look no further. The three stocks that I've listed here have tremendous long-term growth prospects, offer great dividends, and have
Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial
06:04pm, Wednesday, 17'th Sep 2025
Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting
Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms
02:25pm, Wednesday, 17'th Sep 2025
Eli Lilly and Company's hot streak of obesity and type 2 diabetes readouts ended in early August when we saw underwhelming top-line phase 3 results of orforglipron in obesity patients. Orforglipron lo
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
12:26pm, Wednesday, 17'th Sep 2025
Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.
3 Stocks Insiders Are Buying Non-Stop
10:28am, Wednesday, 17'th Sep 2025
Insider buying is one of the few market signals that does not hide behind algorithms or price targets.
Eli Lilly's New Diabetes Drug Shows Better Blood Sugar, Weight Loss Results Than Rival
10:17am, Wednesday, 17'th Sep 2025
The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk's oral semaglutide, and showed greater improvements in blood sugar levels, known as A1C, and greater weight loss.
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
09:00am, Wednesday, 17'th Sep 2025
Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill,
Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy
05:39am, Wednesday, 17'th Sep 2025
Eli Lilly has established itself as the market leader in obesity drugs in Europe, Asia and the Middle East and expects to replicate its U.S. dominance globally, the company's international president t
Eli Lilly cautious on using FDA fast-track voucher for weight loss pill
03:43am, Wednesday, 17'th Sep 2025
Eli Lilly's international president Patrik Jonsson said on Wednesday the company had little clarity on the U.S. Food and Drug Administration's new fast-track review process, cautioning it was too earl
GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
06:46pm, Tuesday, 16'th Sep 2025
Eli Lilly (LLY) concluded the recent trading session at $763.57, signifying a +2.06% move from its prior day's close.
Why Eli Lilly Stock Was a Winner Today
06:15pm, Tuesday, 16'th Sep 2025
A hopeful report about a potential blockbuster drug currently in development and news of an expansion of manufacturing capability helped push Eli Lilly (LLY 2.09%) stock skyward on Tuesday. Shares of
Lilly CEO: U.K. has gone from biopharma leader to laggard
06:02pm, Tuesday, 16'th Sep 2025
Lilly CEO Dave Ricks explains why pricing dynamics in the U.K. make it a very unattractive place for Lilly to invest.
